D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Chemistry D-index 42 Citations 5,592 71 World Ranking 11807 National Ranking 3241

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Enzyme
  • Biochemistry

Chao Yie Yang mostly deals with Biochemistry, Apoptosis, Cell biology, XIAP and Cancer research. His study focuses on the intersection of Apoptosis and fields such as Cell culture with connections in the field of Cell growth, Small molecule, Leukemia, STAT3 and Myeloid leukemia. His research integrates issues of Caspase, Activator and DNA-binding protein in his study of Cell biology.

As part of the same scientific family, Chao Yie Yang usually focuses on XIAP, concentrating on Inhibitor of apoptosis and intersecting with Pharmacology, Orally active, Bioavailability, Antagonist and Cancer cell. His Cancer research research is multidisciplinary, incorporating elements of Clinical trial, Mdm2, Mdm2 p53, Function and STAT protein. His research in Structure–activity relationship intersects with topics in Combinatorial chemistry, Smac mimetics, Protein structure and Stereochemistry.

His most cited work include:

  • The PDBbind database: methodologies and updates. (407 citations)
  • Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. (246 citations)
  • A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment (185 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Cancer research, Small molecule, Biochemistry, Cell growth and Apoptosis. His work carried out in the field of Cancer research brings together such families of science as Proteolysis targeting chimera, Cancer, Molecular biology, Androgen receptor and In vivo. His study in Small molecule is interdisciplinary in nature, drawing from both Ligand binding assay, Biophysics, Stereochemistry, Peptidomimetic and Binding site.

He has included themes like Cell culture, Bromodomain, BRD4, Programmed cell death and Structure–activity relationship in his Cell growth study. His Apoptosis research incorporates elements of Cancer cell, In vitro, Cytotoxicity and Cell biology. His XIAP study integrates concerns from other disciplines, such as Inhibitor of apoptosis, Smac mimetics, Combinatorial chemistry and Bivalent.

He most often published in these fields:

  • Cancer research (28.33%)
  • Small molecule (26.67%)
  • Biochemistry (26.67%)

What were the highlights of his more recent work (between 2018-2021)?

  • Cancer research (28.33%)
  • Cell growth (24.17%)
  • Cancer (10.83%)

In recent papers he was focusing on the following fields of study:

His main research concerns Cancer research, Cell growth, Cancer, Proteolysis targeting chimera and Cell culture. His Cell growth research is multidisciplinary, relying on both Mutation, IC50 and Oral administration, Pharmacology. The study incorporates disciplines such as Receptor, Protein degradation and Proteolysis in addition to Proteolysis targeting chimera.

The research on Cell biology and Biochemistry is part of his Protein degradation project. Chao Yie Yang combines subjects such as EZH2, Myeloid leukemia, Small molecule, Structure–activity relationship and In vivo with his study of Cell culture. The Myeloid leukemia study combines topics in areas such as Cancer cell, Apoptosis, Leukemia and Kinase.

Between 2018 and 2021, his most popular works were:

  • A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo (91 citations)
  • Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. (88 citations)
  • Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. (81 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Enzyme
  • Cancer

His scientific interests lie mostly in Cancer research, Proteolysis targeting chimera, Cell growth, Protein degradation and Proteolysis. His studies in Cancer research integrate themes in fields like Cell culture and STAT3, STAT protein. His research on Cell culture frequently connects to adjacent areas such as In vivo.

To a larger extent, he studies Apoptosis with the aim of understanding STAT3. His Cell growth research integrates issues from Ubiquitin ligase, Receptor and Androgen receptor, LNCaP, Prostate cancer. His Protein degradation study is focused on Biochemistry in general.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

The PDBbind database: methodologies and updates.

Renxiao Wang;Xueliang Fang;Yipin Lu;Chao Yie Yang.
Journal of Medicinal Chemistry (2005)

564 Citations

Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.

Guoping Wang;Zaneta Nikolovska-Coleska;Chao Yie Yang;Renxiao Wang.
Journal of Medicinal Chemistry (2006)

348 Citations

Design of Triazole-Stapled BCL9 α-Helical Peptides to Target the β-Catenin/B-Cell CLL/lymphoma 9 (BCL9) Protein–Protein Interaction

Steven A. Kawamoto;Adriana Coleska;Xu Ran;Han Yi.
Journal of Medicinal Chemistry (2012)

242 Citations

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

Qian Cai;Haiying Sun;Yuefeng Peng;Yuefeng Peng;Jianfeng Lu.
Journal of Medicinal Chemistry (2011)

233 Citations

Design of Small-Molecule Peptidic and Nonpeptidic Smac Mimetics

Haiying Sun;Zaneta Nikolovska-Coleska;Chao Yie Yang;Dongguang Qian.
Accounts of Chemical Research (2008)

216 Citations

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

Bing Zhou;Jiantao Hu;Fuming Xu;Zhuo Chen.
Journal of Medicinal Chemistry (2017)

194 Citations

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Shaomeng Wang;Yujun Zhao;Angelo Aguilar;Denzil Bernard.
Cold Spring Harbor Perspectives in Medicine (2017)

193 Citations

Structure-based design of potent, conformationally constrained Smac mimetics

Haiying Sun;Zaneta Nikolovska-Coleska;Chao Yie Yang;Liang Xu.
Journal of the American Chemical Society (2004)

189 Citations

Analysis of ligand-bound water molecules in high-resolution crystal structures of protein-ligand complexes.

Yipin Lu;Renxiao Wang;Chao Yie Yang;Shaomeng Wang.
Journal of Chemical Information and Modeling (2007)

182 Citations

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.

Yangbing Li;Jiuling Yang;Angelo Aguilar;Donna McEachern.
Journal of Medicinal Chemistry (2019)

158 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Chao Yie Yang

Shaomeng Wang

Shaomeng Wang

University of Michigan–Ann Arbor

Publications: 69

Chandra S. Verma

Chandra S. Verma

Agency for Science, Technology and Research

Publications: 37

Craig M. Crews

Craig M. Crews

Yale University

Publications: 36

Maurizio Pellecchia

Maurizio Pellecchia

University of California, Riverside

Publications: 23

Alessio Ciulli

Alessio Ciulli

University of Dundee

Publications: 18

Hualiang Jiang

Hualiang Jiang

Chinese Academy of Sciences

Publications: 17

Yi Sun

Yi Sun

Zhejiang University

Publications: 17

Jeanne A. Stuckey

Jeanne A. Stuckey

University of Michigan–Ann Arbor

Publications: 16

Michael K. Gilson

Michael K. Gilson

University of Montana

Publications: 16

John C. Reed

John C. Reed

Sanford Burnham Prebys Medical Discovery Institute

Publications: 16

Loren D. Walensky

Loren D. Walensky

Harvard University

Publications: 15

Richard D. Smith

Richard D. Smith

Pacific Northwest National Laboratory

Publications: 14

Alexander D. MacKerell

Alexander D. MacKerell

University of Maryland, Baltimore

Publications: 14

Domenico Delia

Domenico Delia

University of Milan

Publications: 14

Simone Fulda

Simone Fulda

Goethe University Frankfurt

Publications: 13

Cheng Luo

Cheng Luo

Chinese Academy of Sciences

Publications: 13

Trending Scientists

Prasant Mohapatra

Prasant Mohapatra

University of California, Davis

Peter F. Orazem

Peter F. Orazem

Iowa State University

Barry Bosworth

Barry Bosworth

Brookings Institution

Paul Henry Dietz

Paul Henry Dietz

Misapplied Sciences, Inc.

Concepción Domingo

Concepción Domingo

Spanish National Research Council

Matthew Breen

Matthew Breen

North Carolina State University

Marc Montminy

Marc Montminy

Salk Institute for Biological Studies

Ellen G. Strauss

Ellen G. Strauss

California Institute of Technology

Ronald J. Ellis

Ronald J. Ellis

University of California, San Diego

Dimitra Voutsa

Dimitra Voutsa

Aristotle University of Thessaloniki

Igor Timofeev

Igor Timofeev

Université Laval

Martin Hautzinger

Martin Hautzinger

University of Tübingen

Jonathan D. Huppert

Jonathan D. Huppert

Hebrew University of Jerusalem

Tarek A. Yousry

Tarek A. Yousry

University College London

James O. Armitage

James O. Armitage

University of Nebraska Medical Center

Jon Brinkmann

Jon Brinkmann

Apache Corporation

Something went wrong. Please try again later.